ArticleThe EMBO journal2010
TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells.
Article in The EMBO journal, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
109 citing papers in PubMed, 1 synthesis or guideline pooled it, 189 citations in OpenAlex.
- Pooled it
- Epidermal PPARγ Signaling as a Suppressor of Toll-like Receptor-Mediated Inflammation and Fibrosis: Relevance to Cutaneous Squamous Cell Carcinoma.International journal of molecular sciences · 2026Article
- Lipopolysaccharide suppresses lung metastasis by activating CD8BMC cancer · 2026Article
- HMGB1: A Central Node in Cancer Therapy Resistance.International journal of molecular sciences · 2025Review
- Crosstalk Between the Skin Environment and Microbial Community in Immune-Related Skin Diseases.Clinical reviews in allergy & immunology · 2025Review
- Mechanism of action of HMGB1 in urologic malignancies.Frontiers in oncology · 2025Review
- Integrative analysis of crotonylation-associated genes reveals prognostic and therapeutic targets in gliomas.Frontiers in oncology · 2025Article
- Anti-Inflammatory Effects of Extracellular Vesicles fromInternational journal of molecular sciences · 2024Article
- High Mobility Group Box 1 and Cardiovascular Diseases: Study of Act and Connect.Cardiovascular toxicology · 2024Review
- PAM-1: an antimicrobial peptide with promise against ceftazidime-avibactam resistantFrontiers in microbiology · 2024Article
- Progress of research on the relationship between efferocytosis and tumor.Frontiers in oncology · 2024Review
- Unraveling the intricate relationship: Influence of microbiome on the host immune system in carcinogenesis.Cancer reports (Hoboken, N.J.) · 2023Review
- The MyD88 inhibitor, ST2825, induces cell cycle arrest and apoptosis by suppressing the activation of the NF‑κB/AKT1/p21 pathway in pancreatic cancer.Oncology reports · 2023Article
- Immune Checkpoint Inhibitors, Small-Molecule Immunotherapies and the Emerging Role of Neutrophil Extracellular Traps in Therapeutic Strategies for Head and Neck Cancer.International journal of molecular sciences · 2023Review
- Role of the Microbiome in Malignancy.Surgical infections · 2023Article
- PPARs and the Kynurenine Pathway in Melanoma-Potential Biological Interactions.International journal of molecular sciences · 2023Review
- The Formation of NETs and Their Mechanism of Promoting Tumor Metastasis.Journal of oncology · 2023Review
- Carcinogenesis resistance in the longest-lived rodent, the naked mole-rat.Cancer science · 2022Review
- High mobility group box 1 (HMGB1) inhibition attenuates lipopolysaccharide-induced cognitive dysfunction and sickness-like behavior in mice.Immunologic research · 2022Article
- TLR/WNT: A Novel Relationship in Immunomodulation of Lung Cancer.International journal of molecular sciences · 2022Review
49 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Skin cancers are the most commonly diagnosed cancers. Understanding what are the factors contributing to skin tumour development can be instrumental to identify preventive therapies. The myeloid differentiation primary response gene (MyD)88, the downstream adaptor protein of most Toll-like receptors (TLR), has been shown to be involved in several mouse tumourigenesis models. We show here that TLR4, but not TLR2 or TLR9, is upstream of MyD88 in skin tumourigenesis. TLR4 triggering is not dependent on lipopolysaccharide associated to skin-colonizing bacteria, but on the high mobility group box-1 protein (HMGB1), an endogenous ligand of TLR4. HMGB1 is released by necrotic keratinocytes and is required for the recruitment of inflammatory cells and for the initiation of inflammation. The expression of TLR4 on both bone marrow-derived and radioresistant cells is necessary for carcinogenesis. Consistently, a human tissue microarray analysis showed that melanoma and colon cancer display an over-expression of TLR4 and its downstream adaptor protein MyD88 within tumours. Together, our results suggest that the initial release of HMGB1 triggers a TLR4-dependent inflammatory response that leads to tumour development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.